Long-term chloroquine-proguanil malaria prophylaxis in a nonimmune pediatric population

Gozal, David; Fadat, G.; Hengy, C.

doi:10.1016/s0022-3476(05)81869-4

The Journal of Pediatrics

1991

DOI: 10.1016/s0022-3476(05)81869-4

|View full text |Cite

Long-term chloroquine-proguanil malaria prophylaxis in a nonimmune pediatric population

David Gozal

G. Fadat

C. Hengy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1991

2006

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 7 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reliance upon disease symptoms only would impinge on diagnostic accuracy and cause overtreatment. We noted a significant decrease in the time from the institution of appropriate malaria therapy to the disappearance of symptoms in children on Ch-P prophylaxis (8). We were unable to quantify accurately this parameter in the present study.…”

contrasting

confidence: 63%

Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance

Gozal¹,

Hengy²,

Fadat³

1991

Antimicrob Agents Chemother

View full text Add to dashboard Cite

One hundred thirty nonimmune subjects living in Yaounde, Cameroon, completed an 18-month prospective study on the efficacy and safety of weekly chloroquine and daily proguanil (chloroguanide) (Ch-P) in malaria prevention. A total of 9 of 78 Ch-P-treated subjects and 26 of 52 subjects who received no prophylaxis contracted Plasmodium falciarum infection during this period (P < 0.00005). These two groups were comparable for demographic parameters and degree of exposure. Clinical manifestations were of similar severities in the two groups, but parasite counts were significantly higher in the subjects who received no prophylaxis (P < 0.00005). Side effects of prophylaxis were frequent (31%), minor, and related to chloroquine, and they usually resolved within 4 to 6 weeks. Prolonged administration of Ch-P is safe and effectively prevents P. fakciparum malaria in an endemic area with a high prevalence of chloroquine resistance.

show abstract

contrasting

confidence: 63%

Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance

Gozal¹,

Hengy²,

Fadat³

1991

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Efficacy of chloroquine-proguanil chemoprophylaxis against malaria in the Central African Republic

Garín

Lamarque

Ringwald³

et al. 1993

Transactions of the Royal Society of Tropical Medicine and Hygi

View full text Add to dashboard Cite

Efficacy of chloroquine–proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: a case–control study

Matsika-Claquin

Ménard

Fontanet

et al. 2006

Transactions of the Royal Society of Tropical Medicine and Hygi

View full text Add to dashboard Cite

A case-control study was conducted to evaluate the efficacy of the combination of chloroquine plus proguanil as malaria prophylaxis in a non-immune population living in the Central African Republic. Cases were patients presenting with a malaria attack confirmed by a positive blood film and/or an HRP2 positive antigen test at the Pasteur Institute of Bangui. Two control subjects were included per case: one was a relative or close friend and the other was matched to the patient with respect to the length of stay. A questionnaire assessing malaria prophylaxis habits and malarial risk factors over the 2-month period prior to inclusion in the study was given to 48 cases and 96 controls. A conditional logistic regression was used to identify risk factors. The efficacy of the chloroquine plus proguanil regimen was found to be high (95.5%, 95% CI 74.0-99.2%) in this country known for high chloroquine resistance. Our data lend some support to the use of chloroquine plus proguanil in Bangui, and the protective efficacy of chloroquine plus proguanil should now be studied prospectively as part of a randomised controlled trial of various prophylactic drugs.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Long-term chloroquine-proguanil malaria prophylaxis in a nonimmune pediatric population

Cited by 7 publications

References 19 publications

Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance

Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance

Efficacy of chloroquine-proguanil chemoprophylaxis against malaria in the Central African Republic

Efficacy of chloroquine–proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: a case–control study

Contact Info

Product

Resources

About